Derived from the aerospace industry, RRx-001 is a novel multi-effect anticancer drug with properties including macrophage activation, CD47 downregulation, vascular normalization, and epigenetic regulation, it exhibits potent anticancer effects against various cancers, It has been utilized in phase III registered clinical trials for third-line treatment and beyond in small cell lung cancer (Scicinski et al., 2015b; Zhang et al., 2021).RRx-001 may enhance the radiosensitivity of tumor cells by releasing NO, an endogenous vasodilator known to be an effective radiosensitizer. This evidence concerns the gene CD47 and small cell lung carcinoma.